GlaxoSmithKline has agreed to pay $6.2 million to settle a class-action lawsuit against the drugmaker in British Columbia regarding alleged birth defects caused by the antidepressant Paxil, as reported Vancouver Sun Wednesday.
The drugmaker did not admit to wrongdoing or liability under the agreed terms.
GlaxoSmithKline indicated that it reached a settlement "to avoid the time and expense associated with the trial and the subsequent steps in the class-action proceeding."
"We continue to be of the view that the scientific evidence does not establish that exposure to Paxil during pregnancy causes cardiovascular birth defects," the drugmaker contended.
As many as 200 children could be covered under the settlement.
To read more NewsPoints articles, click here.